All News

Moderating a great talk about POTS - great slide & nice presentation technique Dr. Adler flashed a screen of the ROS for pts w/POTs, overwhelming as expected… then overlaid common causes and phenotypes - really like this as a framework! #ACR24 @RheumNow https://t.co/mCmtygxxv4

https://x.com/EBRheum/status/1857812262070714500/photo/1

🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis. Another innovation that may help with the rapid… https://t.co/qSwryK22uj

https://x.com/i/web/status/1857812119326183889

#0456📱 Digital Health & RA ePROs 💻Rx response in 150 RA patients using ePROs & actigraphy 🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone) 💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden. #ACR24 @RheumNow

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

https://x.com/AdelaCastro222/status/1857810860795638038/photo/1

Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk. @RheumNow #ACR24

Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

https://x.com/AkhilSoodMD/status/1857810357684941164/photo/1

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi

Happening now: 16S18 Into the Weeds: Cannabis in Rheum @EleniTiniakou @BharatKumarMD Do you discuss marijuana with your patients? @RheumNow #ACR24

Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https://t.co/OhqTJZQwKX https://t.co/RTQUjE6lLy

Abstr#0647 Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores - Tx: GC, HCQ, AZA @RheumNow #ACR24

Abstract #0614 What is the impact of Lupus on my quality of life? Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM) - high dose GC, comorbidities, and not actively working associated with worse impact on QoL - HCQ shows benefit @RheumNow #ACR24

Lupus symptoms impact tracker | Lupus Foundation of America

#0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow

Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp

https://x.com/synovialjoints/status/1857808573465530859/photo/1

A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm

https://x.com/i/web/status/1857808346730111004

Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA. Makes sense in a way since longer dse duration may play a role. 🔶️THM - screen SpA pts for IBD; ask for GI symptoms @RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z

https://x.com/RHEUMarampa/status/1857808044312125947/photo/1

High PBO effect in PsA studies Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12: 💡PBO rates significantly increased over time. 💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe

https://x.com/i/web/status/1857807792729416051

Lots of ‘CARTS’, not enough ‘work horses’! There are now ~40 CAR-T protocols in #lupus incl many presentations at #ACR24 -most are uncontrolled -selection of pts is key. We need a pathway forward for reg approval & guidelines for studies! @RheumNow @ACRheum 18abst #OOO4 https://t.co/Mckwvn3Ffn

https://x.com/Janetbirdope/status/1857807655235879253/photo/1

#0582🔬Challenges in Achieving PsA Disease Control ➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively 🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes. 🩺Unmet needs remain in PsA; tailored Rx needed #ACR24 @RheumNow

Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW

Topics

All News

Do you get our email newsletter?